Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Angion Biomedica Corp (ANGN)

Angion Biomedica Corp (ANGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,533
  • Shares Outstanding, K 30,113
  • Annual Sales, $ 28,310 K
  • Annual Income, $ -54,570 K
  • 60-Month Beta 0.76
  • Price/Sales 0.91
  • Price/Cash Flow N/A
  • Price/Book 0.52
Trade ANGN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.73
  • Most Recent Earnings -0.21 on 11/14/22
  • Next Earnings Date 11/18/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.36
  • Number of Estimates 3
  • High Estimate -0.21
  • Low Estimate -0.49
  • Prior Year 0.58
  • Growth Rate Est. (year over year) -162.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7800 +5.13%
on 11/09/22
1.0800 -24.07%
on 11/09/22
-0.1548 (-15.88%)
since 11/01/22
3-Month
0.7800 +5.13%
on 11/09/22
1.2600 -34.92%
on 09/12/22
-0.1800 (-18.00%)
since 09/01/22
52-Week
0.7800 +5.13%
on 11/09/22
3.7100 -77.90%
on 12/08/21
-2.5700 (-75.81%)
since 12/01/21

Most Recent Stories

More News
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.

ANGN : 0.8200 (-3.29%)
NBRV : 2.19 (-2.67%)
ASLN : 0.5572 (+1.36%)
IMCR : 59.98 (-4.51%)
Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal

Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the primary and key secondary endpoints. Shares rise.

ANGN : 0.8200 (-3.29%)
AXSM : 71.97 (-0.44%)
ASLN : 0.5572 (+1.36%)
IMCR : 59.98 (-4.51%)
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review

The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.

RHHBY : 41.1400 (+0.54%)
VRTX : 320.76 (+1.38%)
ANGN : 0.8200 (-3.29%)
SRPT : 122.98 (+0.14%)
Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why

Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.

ANGN : 0.8200 (-3.29%)
EDIT : 10.06 (-5.09%)
ASLN : 0.5572 (+1.36%)
IMCR : 59.98 (-4.51%)
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

AZN : 68.34 (+0.54%)
MRK : 109.80 (-0.29%)
ANGN : 0.8200 (-3.29%)
CLVS : 0.3600 (+9.09%)
BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing

The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.

BMRN : 103.02 (+2.02%)
VRTX : 320.76 (+1.38%)
ANGN : 0.8200 (-3.29%)
CELU : 1.7900 (+4.68%)
Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now

Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

ANGN : 0.8200 (-3.29%)
ASLN : 0.5572 (+1.36%)
IMVT : 13.87 (+5.80%)
IMCR : 59.98 (-4.51%)
Merck (MRK) Keytruda Advanced Gastric Cancer Study Meets Goal

Top-line data from a late-stage study shows that Merck's (MRK) Keytruda combined with chemotherapy improved overall survival in patients with advanced gastric cancer.

BMY : 80.88 (+0.75%)
MRK : 109.80 (-0.29%)
VRTX : 320.76 (+1.38%)
ANGN : 0.8200 (-3.29%)
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM

Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.

ANGN : 0.8200 (-3.29%)
SNDX : 25.03 (+4.47%)
BPMC : 47.49 (-0.63%)
IMCR : 59.98 (-4.51%)
Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck

Imago BioSciences (IMGO) to be acquired by pharma-giant Merck (MRK) for $1.35 billion. The transaction is likely to close by first-quarter 2023.

MRK : 109.80 (-0.29%)
VRTX : 320.76 (+1.38%)
ANGN : 0.8200 (-3.29%)
IMGO : 35.72 (+0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

See More

Key Turning Points

3rd Resistance Point 0.8878
2nd Resistance Point 0.8703
1st Resistance Point 0.8451
Last Price 0.8200
1st Support Level 0.8024
2nd Support Level 0.7849
3rd Support Level 0.7597

See More

52-Week High 3.7100
Fibonacci 61.8% 2.5907
Fibonacci 50% 2.2450
Fibonacci 38.2% 1.8993
Last Price 0.8200
52-Week Low 0.7800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar